Founders: Diane and Michael Fagen
Contact Info: firstname.lastname@example.org
26 February 2015 by Dr Irene R. Grant Institute for Global Food Security, Queen’s University Belfast 1 Review of Latest Research on Possible Link Between Mycobacterium avium subsp. paratuberculosis (MAP) and Crohn’s Disease For Advisory Committee on Dangerous Pathogens (ACDP) , 26 February 2015 by Dr Irene R. Grant Institute for Global Food Security, Queen’s University Belfast It is my understanding that the topic of a possible link between MAP and Crohn’s Disease was last discussed by ACDP in 2005/2006 . Th erefore, th is paper will attempt to summarise : (1) studies to detect MAP in CD patients, (2) c urrent expert opinions on the role of MAP in CD, (3) newly suggested associations between MAP and other human conditions, and (4) the potential for humans to be exposed to MAP via contaminated milk and dairy products, up
Attacking the Cause of Crohn's Disease, University of Central Florida, June 2, 2014 UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn’s disease patients. The FDA-approved phase III trial is expected to commence within weeks by RedHill Biopharma, which licensed Naser’s DNA technology for detecting Mycobacterium avium subspecies paratuberculosis, known as MAP. It is believed to be associated with Crohn’s disease. RedHill Biopharma developed the anti-MAP antibiotic regimen known as RHB 104.
UCF researchers closing in on cure for Crohn's disease May 11, 2014 ORANGE COUNTY, Fla. (WOFL FOX 35 ORLANDO) - Dr. Saleh Naser is on a mission. For the last 18-years he's dedicated his life to finding a cure for Crohn's disease. The sometimes debilitating bowel ailment affects hundreds of thousands of Americans. Dr. Saleh and his team at the University of Central Florida say they believe they've found a cure. Their method is in clinical trials right now. FOX 35's Tom Johnson spent a day in Naser's lab to find out how it works and why the researchers are so confident their work will result in a cure.
Dr Behr Discusses Map & Crohn's at the Kingston CCFC Symposium November 2008
Doctor Amy Hermon-Taylor is running for a Crohn's Cure London Marathon, 13th April 2014-------You can also find further information on my campaign, from a more personal perspective, on my justgiving page: www.justgiving.com/Run-For-Crohns-MEN3936 My facebook page: www.facebook.com/RunForCrohns On twitter (I am @RunForCrohns) We are in the process of building a website 'The Crohn's MAP Vaccine: Information and Support Group'. It is not yet live but the linked facebook page went live a few days ago: https://www.facebook.com/pages/Crohns-MAP-Vaccine/427832267319217?ref=hl
PLOS ONE April 2011: Association of Mycobacterium avium subsp. paratuberculosis with Multiple Sclerosis in Sardinian Patients Davide Cossu, Eleonora Cocco, Daniela Paccagnini, Speranza Masala, Niyaz Ahmed, Jessica Frau, Maria Giovanna Marrosu, Leonardo A. Sechi PLOS Published: April 13, 2011 DOI: 10.1371/journal.pone.0018482
February 2013: ResearchGate: Article Mycobacterium avium subsp. Paratuberculosis and multiple sclerosis in Sardinian patients: Epidemiology and clinical features J Frau J Frau D Cossu D Cossu Giancarlo Coghe Giancarlo Coghe L Lorefice L Lorefice G Fenu G Fenu M Melis M Melis [more] Multiple Sclerosis Centre, Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy. Multiple Sclerosis (Impact Factor: 4.82). 02/2013; 19(11). DOI: 10.1177/1352458513477926 Source: PubMed
What is the Crohn's Disease Initiative? A Message from Dr. Chiodini How Can I Help? It has been almost 25-years since I first isolated M. paratuberculosis from a patient with Crohn's disease and suggested that this organism might be the cause of some cases of Crohn's disease. Since that time, I have seen this suggestion turn into a hostile controversy created in large part by the loss of objectivity on both sides of the issue.
Crohn's Forum: Interview with Dr. Hal Gunn, the Founding CEO of Qu Biologics and Developer of "Site Specific Immunomodulation" (SSI) Crohnsforum.com was lucky and managed to (virtually) sit down and have an interview with Dr. Hal Gunn, the founding CEO of Qu Biologics. Qu Biologics is a Canadian company developing an exciting potential treatment for Crohn's disease called, "Site Specific Immunomodulation" (SSI).